Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-375SL as adjunctive maintenance therapy for bipolar 1 disorder
NCT01685151Phase 3Withdrawn
- Sponsor
- Takeda
- Start
- Sep 2012
- Primary completion
- Nov 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ramelteon in bipolar I disorder, sponsored by Takeda. Planned start Sep 2012; status: withdrawn.
02
Drugs
ramelteon
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT01685151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01685151.